Printer Friendly

Allergic Rhinitis Drugs Market Forecast 2014-2024: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines.

NEW YORK, Dec. 10, 2014 /PRNewswire/ -- Report Details Allergic rhinitis drugs C new study showing you trends, R&D progress, and predicted revenues Where is the allergic rhinitis drugs market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 274-page report provides 204 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including: -- Maureen Jenkins, Director of Clinical Services, Allergy UK -- Tonya Winders, President & CEO, Allergy and Asthma Network Mothers of Asthmatics (AANMA) -- Jonathan Bernstein, Professor, University of Cincinnati College of Medicine -- Hazel Econs, Financial & Marketing Director, Allergy Medical UK -- Kimihiro Okubo, Chairman and Professor, Nippon Medical School

Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, you will see forecasts to 2024 for these five submarkets: -- Oral antihistamines -- Intranasal corticosteroids -- Intranasal antihistamines -- Immunotherapy -- Other drugs. Additionally, our new study provides global sales forecasts by volume for the intranasal corticosteroids and intranasal antihistamines submarkets, including individual global sales forecasts by volume for the leading drugs in these submarkets from 2014-2024. Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success. See revenue forecasts for products How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 26 products, including these brands: -- Nasonex -- Allegra/Allegra-D/Allegra OTC -- Zyrtec/Zyrtec D -- Claritin/Claritin OTC -- Astepro -- Avamys/Veramyst -- Xyzal -- Allelock -- Staloral -- Clarinex Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets. What are the prospects in the leading regions and countries? In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024: -- US -- Japan -- China -- Germany -- France -- UK -- Italy -- Spain -- India -- Brazil -- Russia -- Mexico -- Rest of the World There will be growth in established pharma markets and in developing countries. Our analyses show that India, China, Mexico and Brazil, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth Overall world revenue for allergic rhinitis drugs will reach $11.3bn in 2014, our work forecasts. We predict revenue growth from 2014 to 2024. Rising demand for allergic rhinitis drugs, expanding healthcare coverage, economic recovery and the growth of the immunotherapy submarket will increase sales to 2024. Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these: -- ALK-Abello -- GSK -- Johnson & Johnson (J&J) -- Kyowa Hakko Kirin -- Merck & Co. (Merck) -- Sanofi -- Stallergenes -- UCB. A company profile gives you the following information: -- Revenue forecast for allergic rhinitis drugs from 2014 to 2024 -- Discussion of a company's activities and outlook -- Recent financial results -- Assessment of recent developments C mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead. Research and development - assess innovation, trends and possibilities What about R&D - the pipeline for new drugs? You see trends for these areas: -- Oral antihistamines -- Intranasal corticosteroids -- Immunotherapy -- Other progress in allergic rhinitis. Our study also discusses these agents and technologies, among others: -- Subcutaneous immunotherapy -- Sublingual immunotherapy tablets -- Oral antihistamines -- Intranasal corticosteroids -- Novel small molecules including toll-like receptor antagonists. Allergic rhinitis R&D is strong in immunotherapy. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues. What issues will affect the allergic rhinitis drugs industry? Our new report discusses issues and events affecting the allergic rhinitis drugs market. You will find discussions, including qualitative analyses: -- Increasing demand for allergic rhinitis drugs due to increasing prevalence -- A strong immunotherapy R&D pipeline -- Patent expiry and generic competition -- Growth areas such as immunotherapy and combination drugs -- Rx-to-OTC switching -- Pricing and reimbursement issues

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks. How the Allergic Rhinitis Drugs Market Forecast 2014-2024: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines report helps you In summary, our 274-page report gives you the following knowledge: -- Revenues forecast to 2024 for the world allergic rhinitis drugs market and 5 product categories (therapeutic classes) C discover the industry's prospects, finding promising places for investments and revenues -- Revenue forecasts to 2024 for the leading 12 national markets C US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World -- Assessment of 8 leading companies C hear about products, results and strategies including revenue forecasts for allergic rhinitis drugs to 2024 -- Predicted revenues of 26 leading drugs to 2024 C see potentials of top products -- Review of R&D pipelines C investigate developmental trends and progress -- Discussion of what stimulates and restrains companies and the market -- Prospects for established firms and those seeking to enter the market -- View opinions from our survey, seeing interviews with authorities You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Read the full report: http://www.reportlinker.com/p02390351-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergic-rhinitis-drugs-market-forecast-2014-2024-future-prospects-for-companies-in-antihistamines-corticosteroids-immunotherapy--vaccines-300007625.html</a>

SOURCE Reportlinker
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 2014
Words:1190
Previous Article:Asia Pacific NIPT Market Outlook 2018.
Next Article:Planning A Vacation? Don't Forget To Pack A Travel First Aid Kit.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters